MED vs. USNA, NUS, NATR, VERU, EL, IPAR, PBH, HLF, FARM, and JVA
Should you be buying Medifast stock or one of its competitors? The main competitors of Medifast include USANA Health Sciences (USNA), Nu Skin Enterprises (NUS), Nature's Sunshine Products (NATR), Veru (VERU), Estée Lauder Companies (EL), Inter Parfums (IPAR), Prestige Consumer Healthcare (PBH), Herbalife (HLF), Farmer Bros. (FARM), and Coffee (JVA).
Medifast vs.
USANA Health Sciences (NYSE:USNA) and Medifast (NYSE:MED) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, community ranking, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.
54.3% of USANA Health Sciences shares are owned by institutional investors. Comparatively, 95.5% of Medifast shares are owned by institutional investors. 0.3% of USANA Health Sciences shares are owned by company insiders. Comparatively, 2.5% of Medifast shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
USANA Health Sciences received 16 more outperform votes than Medifast when rated by MarketBeat users. However, 63.52% of users gave Medifast an outperform vote while only 60.36% of users gave USANA Health Sciences an outperform vote.
USANA Health Sciences currently has a consensus price target of $36.00, suggesting a potential upside of 20.38%. Medifast has a consensus price target of $16.50, suggesting a potential upside of 16.65%. Given USANA Health Sciences' higher probable upside, analysts clearly believe USANA Health Sciences is more favorable than Medifast.
USANA Health Sciences has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Medifast has a beta of 1.14, indicating that its share price is 14% more volatile than the S&P 500.
Medifast has lower revenue, but higher earnings than USANA Health Sciences. USANA Health Sciences is trading at a lower price-to-earnings ratio than Medifast, indicating that it is currently the more affordable of the two stocks.
USANA Health Sciences has a net margin of 6.30% compared to Medifast's net margin of 0.35%.
In the previous week, USANA Health Sciences had 46 more articles in the media than Medifast. MarketBeat recorded 47 mentions for USANA Health Sciences and 1 mentions for Medifast. Medifast's average media sentiment score of 0.80 beat USANA Health Sciences' score of 0.38 indicating that Medifast is being referred to more favorably in the news media.
Summary
USANA Health Sciences beats Medifast on 8 of the 15 factors compared between the two stocks.
Get Medifast News Delivered to You Automatically
Sign up to receive the latest news and ratings for MED and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medifast Competitors List
Related Companies and Tools
This page (NYSE:MED) was last updated on 3/4/2025 by MarketBeat.com Staff
